Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2218

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2218
---
, financial conditions, results of operations, and prospects.

In
addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any
other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such
activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in
valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our sublicensors
initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual
property that is sublicensed to us. It is possible that such infringement proceedings or defense activities may be less vigorous than
had we conducted them ourselves.

Our
collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our
use of blood and other tissue samples and other materials required for our research and development activities, which they provide to
us, or otherwise arising from the collaboration.

We
collaborate with several institutions, universities, medical centers, physicians and researchers in scientific matters and expect to
continue to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators,
or the written agreements we have do may not cover all instances of medical development that are researched by the counterparty. If we
cannot successfully negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party
collaborator’s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator’s
samples, or data developed in a collaborator’s study, we may be limited in our ability to capitalize on the market potential of
these inventions or developments.

99

Third
parties may assert that we are employing their proprietary technology without authorization.

There
may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods
of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently
pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or
their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to